Antiplatelet therapy after coronary artery bypass grafting is one of the important drug treatments，which plays an active role in improving the rate of venous bridge patency and reducing the incidence of major adverse cardiovascular events（MACE）. Currently，it has been found that some patients have resistance to the commonly used anti-platelet drug clopidogrel，leading to the increased incidence of postoperative vascular bridge stenosis and MACE events，which may be related to the polymorphism of CYP2C19 gene. However，the anti-platelet effect of the third-generation P2Y12 receptor antagonist was not affected by the CYP2C19 genotype.There is an expert consensus that CYP2C19 genotype testing is recommended to determine the dual antibody treatment regimen，so can the individualized treatment regimen based on CYP2C19 genotype testing reduce the incidence of major postoperative cardiovascular adverse events in patients- This paper will review and analyze the relationship between clopidogrel resistance and CYP2C19 genotype，the status quo of anti-platelet therapy after coronary artery bypass grafting and the existing expert consensus recommendation.